Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28272953 | 0.81 | ALDH1A1 (0.42) | CHRNA4ALDH1A1 | |
| SCHEMBL6167528 | 0.73 | CHRNA4 (0.37) | CHRNA4ALDH1A1 | |
| SCHEMBL6168194 | 0.71 | — | — | |
| SCHEMBL6495189 | 0.68 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL28397232 | 0.68 | CHRNA4 (0.35) | CHRNA4ALDH1A1 | |
| SCHEMBL27637650 | 0.67 | GAA (0.52) | CHRNA4ALDH1A1 | |
| SCHEMBL6208343 | 0.64 | CHRNA4 (0.35) | CHRNA4 | |
| SCHEMBL6168602 | 0.63 | SMN1; SMN2 (0.56) | CHRNA4ALDH1A1 | |
| SCHEMBL29021883 | 0.63 | ALDH1A1 (0.32) | CHRNA4ALDH1A1 | |
| SCHEMBL1486240 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254162-A1 | Oxazolidinone derivatives as antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-16 | — | — | US | disclosed |
| US-6734307-B2 | USE AGAINST MULTIPLY RESISTANT GRAM POSITIVE PATHOGENS; HAVE A DIAZINE MOIETY ATTACHED TO THE PHENYLOXAZOLIDINONE WHICH IS FURTHER SUBSTITUTED BY HETEROCYCLIC, ARYL, SUBSTITUTED ARYL, HETEROAROAMATIC RING | RANBAXY LABORATORIES LIMITED (IN) | 2004-05-11 | — | — | US | disclosed |
| EP-1409465-A2 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2004-04-21 | — | — | EP | disclosed |
| EP-1303511-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003007870-A2 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2003-01-30 | — | — | WO | disclosed |
| US-20020103186-A1 | Oxazolidinone derivatives as antimicrobials disease | RANBAXY LABORATORIES LIMITED (IN) | 2002-08-01 | — | — | US | disclosed |
| WO-2002006278-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103186-A1 | Oxazolidinone derivatives as antimicrobials disease | OXA1L, MLYCD, TBCD | CHRNA4 4696/4885ALDH1A1 1168/4885 |
| US-20040254162-A1 | Oxazolidinone derivatives as antimicrobials | PPARD, PDK4, OXA1L | CHRNA4 4269/4885ALDH1A1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.